Global Neurologic Disorders Therapeutics Market 2019-2023 | Advances in Diagnosis to Boost Growth | Technavio

Technavio has published a new market research report on the global neurologic disorders therapeutics market during 2019-2023. (Graphic: Business Wire)

LONDON--()--The global neurologic disorders therapeutics market is expected to post a CAGR of close to 5% during the period 2019-2023, according to the latest market research report by Technavio.

Over the last few years, the market has witnessed the approval of several new drugs for the treatment of various neurological disorders, such as multiple sclerosis. Advances in the research of target identification for multiple sclerosis have led to the identification of an immune cell called CD20-positive B-cell, which is known to play a major role in the progression of the disease. Such advances and approval of new drugs will stimulate the neurological disorders therapeutics market growth during the forecast period.

Looking for more information on this market? Request a free sample report

As per Technavio, advances in the diagnosis of neurogenerative indications will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

Global Neurologic Disorders Therapeutics Market: Advances in Diagnosis of Neurogenerative Indications

The lack of effective diagnostic processes for neurogenerative indications has been one of the major challenges in the neurologic disorders therapeutics market. To overcome this challenge, research is being conducted on novel biomarkers that have the potential to accurately detect these indications. Various potential biomarkers have been discovered and are being studied for the identification of the early stages of Alzheimer’s disease. Such advances in diagnosis are expected to fuel the growth of the market during the forecast period.

“Apart from the advances in the diagnosis of neurogenerative indications, other factors such as drug reformulations, and the advent of regenerative medicines will have a significant impact on the growth of the neurologic disorders therapeutics market value during the forecast period,” says a senior analyst at Technavio.

Global Neurologic Disorders Therapeutics Market: Segmentation Analysis

This market research report segments the global neurologic disorders therapeutics market by application (CNS and PNS), and geographic regions (North America, Europe, Asia, and ROW).

The North American region led the neurologic disorders therapeutics market in 2018, followed by Europe, Asia, and ROW, respectively. The dominance of North America can be attributed to factors such as the strong presence of generics and heavy research on the development of effective therapies in the region.

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

The global neurologic disorders therapeutics market is expected to post a CAGR of close to 5% during the period 2019-2023, according Technavio.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com